Pneumococcal conjugate second or third-dose vaccines (PCVc) in Israel
Israel: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 94.0% in 2025. ▲ Rising
Latest (2025)
94.0%
Change on year
unchanged
World rank
46th
of 194 countries
All-time high
95.0%
in 2018
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Israel, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Israel recorded 94.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025.
That represents a change of unchanged over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Israel peaked at 95.0% in 2018 and was at its lowest, 0.0%, in 2008.
That places Israel 46th out of 194 countries with data for 2025, putting it in the top quarter.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Israel, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 92.0% | — |
| 2012 | 93.0% | +1.1% |
| 2013 | 94.0% | +1.1% |
| 2014 | 94.0% | +0.0% |
| 2015 | 94.0% | +0.0% |
| 2016 | 93.0% | -1.1% |
| 2017 | 94.0% | +1.1% |
| 2018 | 95.0% | +1.1% |
| 2019 | 95.0% | +0.0% |
| 2020 | 94.0% | -1.1% |
| 2021 | 95.0% | +1.1% |
| 2022 | 94.0% | -1.1% |
| 2023 | 94.0% | +0.0% |
| 2024 | 94.0% | +0.0% |
| 2025 | 94.0% | +0.0% |
Israel compared with similar countries
- Israel's 94.0% is above the median for high income countries, which is 91.0%, 1.0× the median. (63 countries reporting)
- Israel's 94.0% is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 1.0× the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 84.4% | 0.0% | 95.0% | 10 |
| 2020s | 94.2% | 94.0% | 95.0% | 6 |
Countries ranked near Israel
More health data for Israel
- Un projection of annual infant deaths, annual growth rate -1.65 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.6956 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 665.9 deaths per 1,000 people (2090)
- Number of infants who die before age 1 119 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2022)
- Population ages 00-04, female, annual growth rate -0.3823 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0445 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.3508 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Israel?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Israel was 94.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Israel?
- The highest recorded value was 95.0% in 2018.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Israel?
- The lowest recorded value was 0.0% in 2008.
- How does Israel rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Israel ranks 46th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Israel?
- Over the last ten years it is unchanged. The long-run trend across the full record is rising.
- Where does this Israel data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).